VAP is a nosocomial infection of the lung tissue that develops more than 48 hours after intubation in mechanically ventilated patients. Critically ill ventilated patients are very susceptible to pneumonia due to an impaired immune system and a breakdown of anatomic barriers that protect the lower respiratory tract. The risk of acquiring VAP increases with older age (>60 years), a history of smoking, alcoholism, prolonged stay in the ICU, and chronic comorbid conditions, such as diabetes and chronic obstructive pulmonary disease.
There are many etiologic agents for VAP. Early-onset VAP (less than 7 days of mechanical ventilation) is usually caused by Haemophilus influenzae, Streptococcus pneumoniae, or Staphylococcus aureus (methicillin-sensitive). Late-onset VAP (>7 days after mechanical ventilation) is usually caused by Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant S aureus (MRSA), and multidrug-resistant gram-negative bacilli. 2 Clinical signs and symptoms for VAP include presence of a new onset of fever, increased productive cough with sputum, leukocytosis, worsening gas exchange, and new pulmonary infiltrates on a chest radiograph. Invasive diagnosis with bronchoalveolar lavage is generally recommended to make a definitive diagnosis.
For the management of VAP, advance practice providers (APPs) should direct initial antibiotic therapy against organisms that are known to frequently cause pneumonia in the ICU. Obtain sputum and blood cultures and initiate appropriate empiric broadspectrum without delay. Therapeutic choices include a combination of ceftazidime and ciprofloxacin, when covering P. aeruginosa, and carbapenems, such as imipenem-cilastatin, when covering extended-spectrum b-lactamase (ESBL)-producing pathogens, such as Klebsiella species. For ICUs with a high prevalence of MRSA, vancomycin should be used.
THE MOST PROBLEMATIC PATHOGENS IN THE INTENSIVE CARE UNIT
Management of infections in the ICU can be challenging due to the rise of multidrugresistant organisms (Box 1). Among the most problematic pathogens are the following:
ESBL-producing Enterobacteriaceae, such as Klebsiella species and Escherichia coli, which may be resistant to penicillins and cephalosporins For most ESBL-producing organisms, carbapenems, such as imipenem and meropenem, are the drugs of choice. P. aeruginosa is one of the leading causes of morbidity in ICU patients, especially those with VAP. It is also a common cause of ICU infections associated with devices and catheters, infections in the urinary tract, and surgical site infections. 3 Increasing rates of multidrug resistance have been noted, especially in immunocompromised hosts (Box 2), those patients with prolonged hospital stays, those patients with invasive devices or mechanical ventilation, and those patients with prior prolonged antibiotic use. Risk factors for acquiring pseudomonal infections are age, comorbidities at ICU admission (such as anemia and burns), and/or invasive devices. For the treatment of problematic multidrug-resistant pseudomonas, current treatment options include the following combinations:
Ceftolozane/tazobactam Ceftazidime/avibactam Piperacillin/tazobactam Cefepime, ceftazidime, or a carbapenem plus an additional agent(s), such as colistin, fosfomycin, aminoglycoside, or a quinolone
APPs working in the ICU should optimize dosing, frequency, and longer infusion time. It is good practice to combine time-dependent antibiotics, including piperacillin/tazobactam, cefepime, and imipenem, with concentration-dependent antibiotics, such as ciprofloxacin or levofloxacin. Acinetobacter baumannii is also a major cause of VAP and bloodstream infections. Risk factors include longer ICU stay, recent surgery, mechanical ventilation, prior antibiotic exposure. Data from the National Nosocomial Infections Surveillance System indicate that resistance of Acinetobacter species is on the rise. 8 For the treatment of susceptible isolates of Acinetobacter, APPs can use Broad-spectrum cephalosporins b-lactam-b-lactamase inhibitor combinations Carbapenems Box 1 Antimicrobial resistance and optimizing antibiotic use in the ICU
Prevalence
The prevalence of multidrug-resistant organisms is increasing in the ICU, 4,5 leading to increased mortality, longer hospital stays, and higher costs.
The emergence of resistance among gram-negative bacteria has significant implications because there are not many therapeutic options.
The most encountered resistant pathogens include MRSA, vancomycin-resistant enterococcus, Enterobacteriaceae (ESBLs), P. aeruginosa resistant to imipenem, and fluoroquinolones.
Risk factors
Features that increase the risk of infection with multidrug resistant organisms in the ICU Optimizing antibiotic therapy in the ICU Principles governing antimicrobial therapy in the ICU include Ensuring adequacy of the initial empiric therapy 5 Timing and rapid initiation of empiric broad empiric broad antibiotics Source-targeted and tissue-targeted therapy (eg, lungs, urinary tract, catheter, and abdomen) Narrow antimicrobial choices based on microbiology and epidemiology data Considering host factors, such as immunosuppression and comorbidities Initial patient response that should guide need for further work or antibiotic duration Treating for the shortest effective duration 6 Avoiding unnecessary combination therapy
For multidrug-resistant Acinetobacter isolates, APPs can use Polymyxins, such as colistin Minocycline Tigecycline Box 2 ICU infections in the immunocompromised patients
Increased risk
Critically ill and immunocompromised patients are at increased risk for community-acquired, opportunistic, and nosocomial infections.
Immunocompromised hosts include patients with neutropenia or hematologic malignancy; those patients on corticosteroids and other forms of immunosuppressive therapy; solid transplant patients; patients with hematopoietic stem transplant, HIV/AIDS, or asplenia; and patients on biologic agents, such as tumor necrosis factor l.
The attenuated inflammatory response in these patients make it difficult to make an early diagnosis because clinical signs and symptoms are frequently atypical and nonspecific.
Because these patients are always put on various prophylactic antimicrobials and have multiple hospitalizations, they are also at increased risk for multidrug-resistant organisms.
Most infections in the immunocompromised patients present in a hierarchical pattern depending on the level of immunosuppression, neutropenia, and CD4 counts.
Because morbidity and mortality are very high, early empiric antimicrobial therapy is universally indicated.
HIV/AIDS
Bacterial pneumonia, bacteremia, gastrointestinal (GI), and central nervous system infections occur at high frequency in HIV/AIDS patients, depending on CD4 1 levels. Pathogens frequently encountered when the CD4 1 levels less than 50 include mycobacterium avium complex, Cryptococcus neoformans, CMV, herpes simplex virus (HSV), and varicella-zoster virus (VZV), although the advent of antiretroviral therapy has reduced the incidence of these pathogens.
S aureus, Streptococcus pneumoniae, and Haemophilus influenzae are the most common fatal bacterial infection in these patients irrespective of CD4 1 levels.
Diarrhea in HIV/AIDS patients is often caused by protozoa Cryptosporidium parvum.
Immune reconstitution inflammatory syndrome, a life-threatening complication of antiretroviral therapy, may occur, leading to an exuberant inflammatory response against a pathogen that may previously been latent.
Neutropenia and other non-HIV immunocompromised hosts
Gram-positive organisms are on the rise in neutropenia patients. These include Staphylococcus, Streptococcus, Enterococcus, and Corynebacterium species. Gram-negative bacilli include Pseudomonas, Escherichia, and Klebsiella species.
Empiric therapy covering both gram-negative and gram-positive organisms is recommended for febrile neutropenic patients
Patients who have undergone solid organ transplantation present with a broad spectrum of infections overtime. 7 During the postoperative period, the common infections include health care-associated pneumonia, urinary tract infections, and catheter-associated and device-associated infections. The risk of opportunistic infections increases over time due to immunosuppressive therapy to prevent organ rejection. 
COMMON VIRAL ILLNESS
Viruses are increasingly being recognized as a major cause of morbidity in the ICU. Table 1 shows the commonly encountered species and their clinical features, workup, management, and prevention. In the ICU, viral illness can be community acquired or nosocomial. Viruses can lead to multiple organ system complications. The most commonly affected systems are the respiratory, GI, neurologic systems, skin, and mucous membranes, which all eventually may lead to sepsis. Viral infections are also a major source of morbidity in the neonatal ICUs (Box 3) and are also a leading cause of central nervous system infections (Box 4). Prompt diagnosis and antiviral therapy are key to good outcomes. For long-term and population-wide prevention, immunization, prophylaxis, and infection control should routinely be encouraged. Viral community-acquired pneumonia is frequently caused by influenza followed by other respiratory viruses, such as parainfluenza, rhinovirus, adenovirus, RSV, and coronaviruses. The symptoms of viral pneumonia may vary from fever to myalgia to arthralgia headache to shortness of breath to cough and to acute respiratory distress syndrome.
APPs working in the ICU need to recognize viral community-acquired pneumonia early and manage it aggressively to prevent complications and improve outcomes. The diagnosis can be made clinically and then confirmed by serology, polymerase chain reaction (PCR), or culture. Treatment is mostly supportive. If the causative agent is influenza, oseltamivir therapy is recommended for adult patients. It can shorten the duration of symptoms and improve outcomes in severe cases. Vaccination is the best preventative measure for these viruses.
Nosocomial viral pneumonia in the ICU is frequently caused by Herpesviridae family of viruses, which include HSV and cytomegalovirus (CMV). Immunocompromised patients are particularly at high risk (see Box 2). HSV can be detected in the throat and 
Bacterial
The most common nosocomial bacterial species among neonates are Staphylococcus, Enterococci, Enterobacter, E coli, and group B streptococcus.
The bloodstream is among the most frequent site of nosocomial infection followed by nosocomial pneumonia; GI; and eye, ear, nose, and throat sites. 8 The major risk factors are poor umbilical handling and central intravenous catheter use.
Viral
Outbreaks of viral infections in the neonatal ICUs are commonly caused by rotavirus, RSV, enterovirus, hepatitis A virus, and adenovirus.
Nosocomial infections can be transmitted via droplet spread, hands of infected hospital personnel and other individuals, contaminated medical equipment, and breast milk from infected mothers. Other pathogens, such as HIV, hepatitis B/C, HSV, VZV, and CMV, can be transmitted vertically from infected mothers.
The clinical manifestations can be severe requiring mechanical ventilation.
Complications associated with nosocomial viral infections can be grouped into 1. Respiratory complications, such as RSV, influenza, parainfluenza, adenoviruses, and coronaviruses 2. GI complications, such as rotavirus (the most common GI virus for infants) 3. Systemic disease, such as enterovirus and parechovirus
Box 4 Common infections of the central nervous system in the ICU patient

Background
In critically ill patients, central nervous infections, such as meningitis and encephalitis, cause significant morbidity and mortality if not diagnosed early and treated promptly.
Bacterial infections can lead to meningitis, brain abscess, subdural empyema, and sepsis. Viral infections can also cause meningitis, encephalitis, optic neuritis, and poliomyelitis.
Bacterial meningitis is often caused by
Streptococcus pneumoniae (the most common causative agent)
Neisseria meningitides
Haemophilus influenzae
Listeria monocytogenes Viral meningitis and encephalitis are often caused by
Enteroviruses
HSV
West Nile virus
Clinical presentation
Meningitis is characterized by the inflammation of the meninges surrounding the brain and the spinal cord.
A triad of fever, nuchal rigidity, and altered mental status in most but not all patients Cranial nerve palsies, nausea, vomiting, headaches, and photophobia
Positive Brudzinski and Kernig signs
Encephalitis is inflammation within the brain parenchyma. Clinical presentation is variable depending on the brain cells affected. Patients are more likely to present with altered level of conscience or confusion, coma, and focal or generalized seizures.
Diagnosis
Suspected patients should receive neuroimaging before lumbar puncture. 9 Bacterial meningitis is confirmed by cerebrospinal fluid (CSF). Positive findings for bacterial meningitis include Elevated opening pressure Polymorphonuclear cell predominance Decreased glucose concentration Elevated protein concentration
In viral meningitis, opening pressure is usually normal, there is lymphocyte predominance, and CSF glucose is usually normal.
Treatment
The antimicrobial agent of choice must penetrate the blood-brain barrier and should be based on patient age and risk factors.
Vancomycin plus ceftriaxone is the preferred empiric therapy.
Ampicillin should be added to the initial empiric therapy in children, immunocompromised hosts, and the elderly (>50 years). 2 Patients with viral encephalitis can be managed with acyclovir.
respiratory secretions by PCR. HSV and CMV are responsive to treatment with acyclovir and ganciclovir, respectively. APPs should ensure universal control precautions when managing these patients.
SUMMARY
Patients in ICUs are more prone to infections and are more likely develop multidrugresistant organisms and have poor outcomes. Multidrug resistance increases mortality and length of stay and is largely responsible for the escalating health care costs in the United States. 10, 11 The clinical manifestations of bacterial and viral infections are highly variable in the ICU patient, ranging from severe respiratory disease to sepsis (Box 5). Early recognition and empiric therapy are recommended but APPs must use antibiotics wisely. ICU APPs should use appropriate initial empiric therapy and de-escalate once cultures and Box 5 Dealing with sepsis and systemic inflammatory response syndrome in the ICU Sepsis is a systemic inflammatory response syndrome that results from an infection.
Sepsis is described as severe if a patient develops end-organ dysfunction and hypotension that is not responsive to fluid resuscitation.
The spectrum of sepsis causing pathogens is rapidly changing from predominantly gramnegative organisms to gram-positive organisms. When sepsis is suspected, clinicians should rapidly administer broad-spectrum antibiotics.
The Surviving Sepsis Campaign bundle 12 recommends the following: Measure and monitor lactate level. Obtain blood cultures prior to administration of antibiotics. Begin rapid administration of crystalloid to manage hypotension and elevated lactate (>4 mmol/L). Apply vasopressors if patient is hypotensive during or after fluid resuscitation to maintain mean arterial pressure 65 mm Hg.
Managing a sepsis patient involves a lot of supportive care. The first few hours should be dedicated to restoring adequate perfusion, providing antibiotics, and optimizing oxygen supply and demand susceptibility data are available. The emerging and re-emerging infectious pathogens as well as drug resistance involving Enterobacteriaceae species, Acinetobacter baumannii, and Pseudomonas should be considered a major threat to public health. There is a need for the development of new and more effective drugs. Vaccinations and effective infection control practice should be emphasized globally.
